S Haller1,2,3,4, M-L Montandon2,5, C Rodriguez6, M Ackermann5, F R Herrmann2,7, P Giannakopoulos2,6. 1. From the Affidea Centre de Diagnostic Radiologique de Carouge (S.H.), Geneva, Switzerland sven.haller@me.com. 2. Faculty of Medicine (S.H., M.-L.M., F.R.H., P.G.), University of Geneva, Switzerland. 3. Departments of Surgical Sciences and Radiology (S.H.), Uppsala University, Uppsala, Sweden. 4. Department of Neuroradiology (S.H.), University Hospital Freiburg, Freiburg, Germany. 5. Department of Mental Health and Psychiatry (M.-L.M., M.A.). 6. Division of Institutional Measures, Medical Direction (C.R., P.G.). 7. Division of Geriatrics, Department of Internal Medicine, Rehabilitation and Geriatrics (F.R.H.), University Hospitals of Geneva, Geneva, Switzerland.
Abstract
BACKGROUND AND PURPOSE: The presence of apolipoprotein E4 (APOE*E4) is the strongest currently known genetic risk factor for Alzheimer disease and is associated with brain gray matter loss, notably in areas involved in Alzheimer disease pathology. Our objective was to assess the effect of APOE*E4 on brain structures in healthy elderly controls who subsequently developed subtle cognitive decline. MATERIALS AND METHODS: This prospective study included 382 community-dwelling elderly controls. At baseline, participants underwent MR imaging at 3T, extensive neuropsychological testing, and genotyping. After neuropsychological follow-up at 18 months, participants were classified into cognitively stable controls and cognitively deteriorating controls. Data analysis included whole-brain voxel-based morphometry and ROI analysis of GM. RESULTS: APOE*E4-related GM loss at baseline was found only in the cognitively deteriorating controls in the posterior cingulate cortex. There was no APOE*E4-related effect in the hippocampus, mesial temporal lobe, or brain areas not involved in Alzheimer disease pathology. Controls in the cognitively deteriorating group had slightly lower GM concentration in the hippocampus at baseline. Higher GM densities in the hippocampus, middle temporal lobe, and amygdala were associated with a decreased risk for cognitively deteriorating group status at follow-up. CONCLUSIONS: APOE*E4-related GM loss in the posterior cingulate cortex (an area involved in Alzheimer disease pathology) was found only in those elderly controls who subsequently developed subtle cognitive decline but not in cognitively stable controls. This finding might explain the partially conflicting results of previous studies that typically did not include detailed neuropsychological assessment and follow-up. Most important, APOE*E4 status had no impact on GM density in areas affected early by neurofibrillary tangle formation such as the hippocampus and mesial temporal lobe.
BACKGROUND AND PURPOSE: The presence of apolipoprotein E4 (APOE*E4) is the strongest currently known genetic risk factor for Alzheimer disease and is associated with brain gray matter loss, notably in areas involved in Alzheimer disease pathology. Our objective was to assess the effect of APOE*E4 on brain structures in healthy elderly controls who subsequently developed subtle cognitive decline. MATERIALS AND METHODS: This prospective study included 382 community-dwelling elderly controls. At baseline, participants underwent MR imaging at 3T, extensive neuropsychological testing, and genotyping. After neuropsychological follow-up at 18 months, participants were classified into cognitively stable controls and cognitively deteriorating controls. Data analysis included whole-brain voxel-based morphometry and ROI analysis of GM. RESULTS:APOE*E4-related GM loss at baseline was found only in the cognitively deteriorating controls in the posterior cingulate cortex. There was no APOE*E4-related effect in the hippocampus, mesial temporal lobe, or brain areas not involved in Alzheimer disease pathology. Controls in the cognitively deteriorating group had slightly lower GM concentration in the hippocampus at baseline. Higher GM densities in the hippocampus, middle temporal lobe, and amygdala were associated with a decreased risk for cognitively deteriorating group status at follow-up. CONCLUSIONS:APOE*E4-related GM loss in the posterior cingulate cortex (an area involved in Alzheimer disease pathology) was found only in those elderly controls who subsequently developed subtle cognitive decline but not in cognitively stable controls. This finding might explain the partially conflicting results of previous studies that typically did not include detailed neuropsychological assessment and follow-up. Most important, APOE*E4 status had no impact on GM density in areas affected early by neurofibrillary tangle formation such as the hippocampus and mesial temporal lobe.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin Journal: Neurobiol Aging Date: 2010-08 Impact factor: 4.673
Authors: Po H Lu; Paul M Thompson; Alex Leow; Grace J Lee; Agatha Lee; Igor Yanovsky; Neelroop Parikshak; Theresa Khoo; Stephanie Wu; Daniel Geschwind; George Bartzokis Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: H A Wishart; A J Saykin; T W McAllister; L A Rabin; B C McDonald; L A Flashman; R M Roth; A C Mamourian; G J Tsongalis; C H Rhodes Journal: Neurology Date: 2006-10-10 Impact factor: 9.910
Authors: A Hämäläinen; M Grau-Olivares; S Tervo; E Niskanen; C Pennanen; J Huuskonen; M Kivipelto; T Hänninen; M Tapiola; M Vanhanen; M Hallikainen; E-L Helkala; A Nissinen; R L Vanninen; H Soininen Journal: Neurodegener Dis Date: 2008-03-06 Impact factor: 2.977
Authors: Margaret Abraham; Michael Seidenberg; Dana A Kelly; Kristy A Nielson; John L Woodard; J Carson Smith; Sally Durgerian; Stephen M Rao Journal: J Int Neuropsychol Soc Date: 2020-03-05 Impact factor: 2.892
Authors: Marc A Khoury; Mohamad-Ali Bahsoun; Ayad Fadhel; Shukrullah Shunbuli; Saanika Venkatesh; Abdollah Ghazvanchahi; Samir Mitha; Karissa Chan; Luis R Fornazzari; Nathan W Churchill; Zahinoor Ismail; David G Munoz; Tom A Schweizer; Alan R Moody; Corinne E Fischer; April Khademi Journal: Brain Sci Date: 2022-05-05
Authors: Alexandra Badea; Didong Li; Andrei R Niculescu; Robert J Anderson; Jacques A Stout; Christina L Williams; Carol A Colton; Nobuyo Maeda; David B Dunson Journal: Front Neurosci Date: 2022-06-17 Impact factor: 5.152
Authors: Merel van der Thiel; Cristelle Rodriguez; Dimitri Van De Ville; Panteleimon Giannakopoulos; Sven Haller Journal: Front Aging Neurosci Date: 2019-02-19 Impact factor: 5.750